Physician profile
Antwan D Robinson
NPI 1073635132
$3,889.35
in general payments reported to CMS, 2019-2025
26 companies · $1,591 in 2025
The $1,591 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,070 · 2020: $323 · 2021: $309 · 2022: $50.21 · 2023: $78.33 · 2024: $469 · 2025: $1,591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,727 · Travel and Lodging: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.99 |
| Travel and Lodging | $411.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $857.38 | 2024-2025 | General - Vascular Access, Watchman Access System |
| Abiomed | $792.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $408.08 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $379.86 | 2023-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $308.82 | 2021 | |
| Bard Peripheral Vascular, INC. | $212.30 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $189.61 | 2019-2025 | Lifevest |
| Pfizer INC. | $169.86 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $104.54 | 2019 | |
| Medtronic Vascular, INC. | $101.47 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $49.40 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.83 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $41.40 | 2025 | Wegovy |
| Amgen INC. | $41.22 | 2019-2024 | Repatha |
| Acist Medical Systems, INC. | $24.66 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $22.84 | 2025 | Amvuttra |
| Inspire Medical Systems, INC. | $21.76 | 2025 | Inspire |
| Abbott Laboratories | $20.40 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Merck Sharp & Dohme LLC | $16.39 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.09 | 2025 | |
| Amarin Pharma, INC. | $14.88 | 2020 | |
| Philips North America LLC | $14.57 | 2020 | |
| Glaxosmithkline, LLC. | $14.10 | 2025 | Shingrix, Arexvy |
| Lexicon Pharmaceuticals, INC. | $13.26 | 2024 | |
| Angiodynamics, INC. | $11.04 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antwan Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.